MedTrace Logo

Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome

NCT00997750 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2009-10-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether nonsteroidal antiinflammatory drug lornoxicam in combination with low dose aspirin (100mg/day) is effective and safe in patients with Acute Coronary Syndrome without persistent ST-segment elevation.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Lornoxicam

lornoxicam 8mg/day and 12mg/day for 15 days

Sponsors & Collaborators

  • Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation

    lead OTHER_GOV

Principal Investigators

  • Alexei K Gruzdev, Prof · Department of Cardiology, Central Clinical Hospital of Presidential Administration of Russian Federation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-12-31
Completion
2009-06-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00997750 on ClinicalTrials.gov